Weight-loss drug developers line up to tap lucrative market as competition heats up

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up

Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...

Ozempic Comes To India At Rs 2,200 Weekly Dose, Novo Nordisk Cautions Against Unsupervised Use

Ozempic has been approved for type-2 diabetes, while Novo Nordisk’s other global blockbuster Wegovy is targeted at obesity.
newscase

Novo Nordisk Shares Plunge as Weight-Loss Drug Dominance Fades

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

Missed Ozempic? Lilly's Next Drug Could Be Even Bigger

Lilly's next-generation obesity shot is starting to look like the company's most powerful swing yet in a market investors ...
NDTV Profit

Lilly's Experimental Shot Cuts Body Weight By 23% In Study

The latest results will help cement Lilly's dominance in the obesity market that's expected to hit $100 billion by 2030.

Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...

Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global Insights

Shortly after, Novo Nordisk's CEO Mike Doustdar signaled the company is "all in" on the forthcoming launch of oral semaglutide, emphasizing robust supply readiness ahead of the anticipated year-end ...